Patton named CEO of OneOncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jeff Patton was named chief executive officer of OneOncology. Patton has been Acting CEO and president of Physician Services since February.

Jeff Patton

OneOncology includes five practices throughout the U.S., represents over 400 providers, and cares for approximately 250,000 patients annually at 160 sites of care. OneOncology partner practices deliver integrated oncology care services including screening and diagnosis, clinical trials, therapies, and survivorship or end-of-life care. A main responsibility of OneOncology is to help its partner practices expand services in cancer care.

“We formed OneOncology in 2018 with the idea that with physician leadership, common technology platforms, and access to capital, practices could have both the necessary scale and local decision-making authority needed to not only survive but thrive in today’s marketplace,” Patton said in a statement. “Today, as practices grapple with COVID-19 and plan for caring for patients post peak, the ideas that brought us together are exactly what will propel our future growth.”

Patton will continue as the executive chairman of the board at Tennessee Oncology.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login